vials, and the prescribing information specifies a dosing regimen of 2 mg/kg at 0 and 4 weeks and then every 8 weeks thereafter. The purpose of this study was to examine the patterns of prescribing and administration of GLM-IV, including the demographic, clinical, and utilization characteristics of patients with RA newly treated with GLM-IV.
Methods: Rheumatology practices across the continental United States were solicited for a chart-review study. Inclusion criteria were: (1) diagnosis of RA; (2) current treatment with GLM-IV; (3) age Z18 years; and (4) lack of pregnancy (in female patients). Physicians were offered a monetary incentive for each eligible chart provided. An electronic case-report form was developed to aid in the chart data extraction and included fields for demographic characteristics, available comorbid diagnoses, prior RA treatments, and doses and dates of GLM-IV administration.
Findings: A total of 117 eligible patient charts from 15 rheumatologist practices were reviewed. The patient sample was predominantly female (81.2%), with a mean (SD) age of 55.4 (14.5) years. A total of 55.6% of patients had evidence of biologic treatment before receiving GLM-IV, and 53% had at least 1 comorbid condition. In total, 300 individual GLM-IV infusions from this sample were reviewed. Due to the relatively recent approval of GLM-IV use by the US Food and Drug Administration, the majority of patients in this sample (69.2%) had received only between 2 and 4 infusions at the time of the review. For infusion records with valid dose data, the mean number of administered vials was 3.6 (0.8) (total dose, 180 mg); the majority of patients received a dose consistent with the prescribed dose of 2 mg/kg. Combination therapy with methotrexate was observed in the charts of a minority of patients (27.4%) . The mean interval between induction and the first follow-up infusion was 32.9 (11.4) days, with a mean maintenance interval of 56.5 (13.3) days.
Implications: This analysis provides an early glimpse of the patterns of prescribing GLM-IV. Overall, patients appeared to have been receiving GLM-IV in accordance with Food and Drug Administration labeling; although the rate of prescribing methotrexate was low, dosages and administration intervals were within the expected ranges.
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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints and surrounding tissues, and affects approximately 1% of the global population. 1 Treatment for RA is focused on reducing and controlling the inflammation that drives tissue damage and disease progression. Historically, disease-modifying antirheumatic drugs (DMARDs) have been the mainstay of RA treatment. However, over the past decade, the treatment of RA has improved significantly with the introduction of biologic DMARDs. These biologic therapies specifically target and neutralize proinflammatory cytokines and suppress immune-cell activation. 2 The first biologics targeted tumor necrosis factor (TNF)-α, and now make up the primary class of biologics used for treating RA; biologics with other mechanisms of action, targeting different pro-inflammatory cytokines and immune-cell activation, are also available and typically are used after nonresponse with anti-TNF agents. 3 Because RA is a chronic disease, and because biologic medications may lose efficacy over time, some patients are prescribed multiple biologics over the course of the disease. Switches between biologic agents occur both within the anti-TNF class and across other mechanisms of action. [4] [5] [6] [7] Each biologic medication has a unique dosing regimen. Biologics may or may not include an induction period and range from daily administration to administration once every 8 weeks. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Biologic medications must be administered parenterally and are available as subcutaneous and/or intravenous formulations. Although the route of administration (ROA) has been reported not to affect the efficacy of biologic medications, dosing regimens, as well as a patient's preference for and comfort with a specific ROA, may affect medication adherence and treatment efficacy. [18] [19] [20] [21] [22] [23] In some cases, patients and providers are most comfortable with the medications and the ROAs with which they have experience, whereas for others, particular aspects of treatment, such as medical oversight of intravenous administration or at-home administration of subcutaneous formulations, drive preferences. 20, 22, 24 In July 2013, the US Food and Drug Administration (FDA) approved the use of intravenous golimumab (GLM-IV), in combination with methotrexate, for the treatment of moderate to severe, active RA. 13 GLM-IV is a fully human monoclonal antibody specific for human TNF-α and is administered as 2 mg/kg IV infused over 30 minutes at weeks 0 and 4 (induction) then every 8 weeks thereafter (maintenance). 25 Although anti-TNF biologics are the class of biologic DMARDs most commonly used for the treatment of RA, GLM-IV is only the second intravenously administered anti-TNF biologic approved for the treatment of RA. In contrast, 4 of the 6 anti-TNF biologics approved for the treatment of RA are administered subcutaneously. The primary purpose of this study was to examine the early patterns of prescribing and administration of GLM-IV in patients with RA through a review of patients' charts; secondary study end points included assessments of the demographic and clinical characteristics of patients newly prescribed GLM-IV. Analyses focused on how the observed GLM-IV prescribing patterns compared with recommended guidelines, and on patients' history of biologic medications.
MATERIALS AND METHODS Study Sites
This study was limited to rheumatologists practicing in the United States. Among these practitioners, a subset of those who prescribed GLM-V were identified and contacted by telephone to determine whether they were eligible and willing to participate in the study. Rheumatologists who agreed to participate and who had prescribed GLM-IV to at least 1 patient were then recruited into the study. All providers were offered an initial incentive of $400 for agreeing to participate and an additional $50 for every chart identified as eligible for review. To be included in the study, providers were required to complete study contracting and to provide at least 1 eligible patient chart. Of the 300 sites contacted, 15 providers' practices across 12 states participated in the study ( Table I) . Contracted providers were not asked about prior participation in clinical trials of biologic DMARDs. Appropriate institutional review board approval was obtained from Essex IRB (Lebanon, New Jersey) before the recruitment of providers and before the review of patients' charts.
Inclusion/Exclusion Criteria
To be included in the study, patients' charts were required to have had evidence of a diagnosis of RA and at least 1 infusion of GLM-IV. Additionally, inclusion was limited to patients at least 18 years of age. Charts of pregnant female patients were not included in this study.
Data Collection
A database (Access; Microsoft Corp., Redmond, Washington) was developed as the case-report form and was designed to mimic a Web page interface for ease of data entry. Data-entry forms were separated into subject tabs and included patients' characteristics, comorbidity data, GLM-IV data, combination therapy administered with GLM-IV, and previous RA treatments. Specific variables associated with GLM-IV infusions included date of administration, administered quantity, and patients' weight. Of the 15 provider practices that agreed to participate in the study, 12 directly transferred patients' charts and 3 required on-site data abstraction. Six research staff members, each trained in the privacy laws and general research ethics of the Health Insurance Portability and Accountability Act, performed the chart review and data abstraction. In total, 117 eligible charts from RA patients were reviewed. Chart composition varied markedly across patients and sites, with the review of a single chart taking a mean duration of 60 minutes. Chart information dating back a maximum of 5 years from the most recent GLM-IV infusion was extracted.
Data Analysis
The dataset resulting from the chart review was analyzed. Descriptive statistics, including means (SD) and frequencies (%) of the characteristics of the patients and of the GLM-IV administrations are presented. For those patients with evidence of prior biologic use, descriptive statistics for the number, medication, and ROA of prior treatments were also calculated.
RESULTS
Patients included in this study were predominantly female (n ¼ 95 [81.2%]), with a mean age of 55.4 (14.5) years (Table II) . Data on ethnicity and insurance type were not present in the charts from a majority of the patients (59.8% and 68.4%, respectively). Based on available ethnicity and insurance data, the sample was composed of 38 white patients, 6 black, 2 Hispanic, and 1 designated as "other"; commercial insurance was the most common coverage type (23), followed by Medicare (13). Regarding comorbidities, 22.2% of the sample had documented evidence of a comorbid diagnosis of hypertension; 19.7%, depression; and 16.2%, hyperlipidemia/ hypercholesterolemia (Table II) .
Among the 117 patients in the sample, 300 individual GLM-IV infusions were identified, with the (Table III) . Infusion records suggested that most patients received the correct number of vials to yield a prescribing dose of 2 mg/kg, with a mean of 3.6 (0.8) vials administered (dose, 180 mg). Record keeping differed across providers, with some recording the number of vials infused (with or without a wasted amount), others providing the dose administered in milligrams, and some providers recording both. In cases in which an incorrect number of vials was administered, the reason was a minor discrepancy between the recommended dose and the vial contents (50 mg), and the dose tended to be slightly low to avoid the use of another vial. For example, a patient whose prescribed dose at 2 mg/kg was 104 mg may have been administered 2 vials (dose, 100 mg). The mean interval between induction and the first follow-up infusion was 32.9 (11.4) days, with a mean maintenance interval of 56.5 (13.3) days.
Combination therapy with GLM-IV and methotrexate was reported in 27.4% of patients' charts. Another 12.8% of patients had documentation that they were unable to tolerate methotrexate, leaving 59.8% of patients with no accessible documentation of having received combination with methotrexate (Table III) . Table IV to Table VI display data on previous biologic use among the sample. Sixty-five patients (55.6%) had evidence of having received biologic treatment preceding GLM-IV initiation ( Table IV (Table IV) . These rates of market uptake are consistent with those from other studies, as adalimumab, etanercept, and infliximab are the anti-TNF therapies most commonly prescribed firstline. 4, 26, 27 Regarding biologic ROA, 41.5% of patients had received only subcutaneously administered treatments, 21.5% had received only infusible treatments, and 20.0% had received a combination of subcutaneous and infusible treatments before initiating treatment with GLM-IV ( Table IV) . The remaining patients had evidence of either abatacept or tocilizumab administration in their records, both of which are available in subcutaneous and intravenous formulations and therefore could not be assigned to a particular ROA.
DISCUSSION
The findings from this study provide a glimpse of the early prescribing patterns of GLM-IV. On the whole, the demographic characteristics of this sample of GLM-IV users were similar to those of the overall population with RA-primarily female and of middle age. 1, 28 The most commonly reported comorbidities were hypertension (22.2%), depression (19.7%), and hyperlipidemia/hypercholesterolemia (16.2%), consistent with those from previous reports of the RA population. 29, 30 Most patients initiating GLM-IV had used a biologic earlier in their treatment (55.6%), although GLM-IV was being used as a first-line biologic therapy in 44.4% of the sample population. The rate of prior biologic use in this sample of patients with RA who used GLM-IV was 28 There were no differences in sex or age between the subsets of biologic-experienced and biologic-naïve patients included in this chart review. The proportion of patients who were biologic naïve before taking GLM-IV was higher than expected at the outset of the study, as GLM-IV was recently approved in July 2013. Of the 117 charts examined, 52 did not have evidence of prior biologic use. As the chart review looked back only 5 years, a definitive statement regarding patients' previous experience with biologics cannot be made and may have partially accounted for the high percentage of biologic-naïve patients observed in this study. There are several reasons that could lead to the first-line prescribing of this anti-TNF biologic DMARD. First, although the intravenous formulation is new, the drug itself is not entirely new. The use of the subcutaneous formulation of golimumab was approved in April 2009. Therefore, it is possible that providers are more comfortable with GLM-IV than they would be with an entirely new pharmaceutical. Furthermore, GLM-IV and infliximab are the only 2 intravenous anti-TNF inhibitors, and the lack of choice compared with the subcutaneous anti-TNF inhibitor market could have accounted for the increased use of GLM-IV in biologic-naïve patients. Many of the providers who participated in the study had an infusion center on-site, which has been reported to be associated with the increased use of infusible biologics. 27 The propensity of the contracted providers to try their patients on new medications was not assessed in this study, but providers hesitant to prescribe new medications would likely not have been included in this study because of the requirement of having treated at least 1 patient with GLM-IV.
In the cohort of biologic-experienced patients, the use of a single prior biologic predominated. In this group of 46 individuals who had used 1 prior biologic, infliximab was the most commonly cited treatment, used by 30.4% (Table V) . This finding might suggest a preference for intravenous administration in a subset of this sample, as infliximab is the only other intravenous anti-TNF biologic available. 31 In the majority of the sample with single prior biologic use (54.3%), GLM-IV was switched from a subcutaneous medication. In another 7 individuals (15.2%), GLM-IV was switched from tocilizumab or abatacept, each of which is available in both subcutaneous and intravenous formulations, placing the percentage of patients remaining with the intravenous ROA between 30.4% and 45.6% (Table V) . In this sample of 46 patients who had used one prior biologic, the rate of biologic use did not follow the rates of market penetration, with certolizumab being used more frequently than etanercept, one of the most commonly prescribed first-line anti-TNF therapies. 4, 26, 27 The use of certolizumab at such a high rate, as well as the first-line use of tocilizumab, were unexpected and may suggest prior use of other biologic agents before the start of the 5-year chart-review period.
Although ROA does not appear to have been the driving force behind the choice of GLM-IV in this sample, as less than half of the patients were switched from an intravenous biologic, there was still a clear preference for the intravenous ROA in a subset of these patients. The switch to GLM-IV in itself may also suggest a patient's or provider's preference for IV administration in certain cases, as there are several subcutaneous anti-TNFs that can be prescribed after nonresponse to a first-line treatment. The move to an intravenous therapy on nonresponse to a subcutaneous biologic could be linked to a belief that intravenous administration can provide a more personalized dose than subcutaneous administration because the dose can be exactly matched to a patient's weight, or a desire to more closely monitor a patient's adherence to a medication regimen because intravenous medications are administered in the physician's office. A patient's perception of increased safety has also been reported with intravenous administration, due to the increased involvement of medical professionals in the process, and may be a factor in providers' and patients' decisions. 20, 24, 32 Lastly, providers who offer, and can bill for, infusion services have been shown to have a preference for the intravenous ROA. 27 Further study of the motivations regarding the choice of a specific biologic, on the part of both the physician and the patient, is warranted.
There was also an increased rate of subcutaneous biologic use by the sample of patients who had used 2 or more biologics previously (n ¼ 19). Of these patients, all had prior use of at least 1 subcutaneous anti-TNF biologic, with etanercept being the most commonly used ( Table V) . The majority of these patients (13 of 19) also had experience with an intravenous biologic; again, infliximab was the most common. There were no patients who used exclusively intravenous biologics before starting treatment with GLM-IV, but this is likely in part due to the scarcity of IV anti-TNF biologics, because individuals using 2 prior biologics had experience only with anti-TNFs. The use of biologics with other mechanisms of action by patients with documented previous use of Z2 biologics occurred after the trial of at least 1 anti-TNF biologic. In some patients with prior use of multiple biologics, anti-TNFs were observed both before and after the use of biologics with alternative mechanisms of action. In all individuals who used 3 or more biologics in the previous 5 years, treatment had been switched at some point to a biologic with an alternative mechanism of action. Overall, the dose and administration of GLM-IV were in accordance with FDA-approved labeling, although the rates of GLM-IV use in combination with methotrexate were low. In general GLM-IV was dosed at a level consistent with the 2-mg/kg recommended dose. In some cases, the dose administered was slightly less than 2 mg/kg, most often due to the dose having just exceeded that which could be achieved using a whole number of vials. In all but 3 of these cases, the recorded doses were within 10% of dose by weight. Documentation of combination therapy with methotrexate, as included in the GLM-IV label, was only found for 40.2% of patients. Approximately one third of patients (27.4%) were receiving GLM-IV in combination with methotrexate, as included in the GLM-IV labeling; 12.8% of patients were not, with an intolerance to methotrexate documented in their charts. No documentation regarding methotrexate was available in the remaining 59.8% of charts. Although combination therapy is known to be used at lower rates than recommended, the use of GLM-IV and methotrexate by one third of patients is still lower than expected. 27, 33 Due to the proximity in time of the chart collection and GLM-IV approval (July 2013), most patients were early in their treatment regimens, with over half of patients (53.8%) still in the induction dosing phase (2 infusions over a period of 4 weeks). The majority of the patients in the maintenance phase of treatment had received 3 infusions, with only 21.4% of patients having received 4 or more infusions (Table III) .
Although chart review can provide a comprehensive assessment of a patient's clinical characteristics and disease treatment history, not all aspects of a patient's care regimen can be assessed through these means, especially considering the fragmented nature of the health care system. This study reviewed rheumatologists' charts for the assessment of the characteristics of patients with RA and their treatment histories. As rheumatologists are specialists who treat a specific aspect of a patient's overall health care needs, all of the patients reviewed here were likely to have been seeing another physician for their general health care; patients may have also seen multiple rheumatologists over their course of disease. The level of communication between these providers remains unknown, and it is possible that charts from the practices of primary care physicians and rheumatologists would shed different light on the same patient. Therefore, the full picture of a patient's health care and treatment strategy may not be available from the review of a single chart. In addition, chart documentation varies dramatically among providers and practices, resulting in varying levels of information and detail in each chart. For example, the lack of patient demographic data available in this study may have been, in part, due to chart documentation; the low rates of GLM-IV administration in combination with methotrexate may also have been affected by differences in documentation across various providers. Lastly, charts are intended as a tool for providers to use in the ongoing assessment of a patient's clinical status and disease progression. Therefore, the patient's perspective is generally not available, leading to only a provider's assessment of the patient's disease state and quality of life.
This study reviewed early GLM-IV use in a population of patients with RA newly initiated on treatment with GLM-IV. The information on dose and administration and patients characteristics collected suggest GLM-IV prescribing and administration in accordance with the FDA-approved labeling in this heterogeneous sample of patients with RA. Just under half of GLM-IV users were biologic naïve; biologic-experienced patients had used between 1 and 7 prior biologics. Most patients were early in their treatment plans, likely due to the close timing of the chart review in relation to the approval of GLM-IV. The rate of GLM-IV administration in combination with methotrexate was low in this population, but patients generally received a dose of 2 mg/kg of GLM-IV, consistent with FDAapproved labeling. This study is the first to report on GLM-IV users' characteristics via chart review. Follow-up studies on the patterns of prescribing and administration GLM-IV, after it has been available for a longer period and after physicians and patients have become more familiar with the medication, are warranted. reimbursement and the management of electronic medical record transfers. V. Arrington, J. Cleary, T. Kimmitt, A. Lansinger, P. Straub, and B. Tompkins are acknowledged for their roles in chart review and data extraction.
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